Centessa Pharmaceuticals (CNTA) Competitors

Centessa Pharmaceuticals (NASDAQ:CNTA) and DICE Therapeutics (NASDAQ:DICE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Does the MarketBeat Community favor CNTA or DICE?

Centessa Pharmaceuticals received 12 more outperform votes than DICE Therapeutics when rated by MarketBeat users. Likewise, 56.00% of users gave Centessa Pharmaceuticals an outperform vote while only 40.00% of users gave DICE Therapeutics an outperform vote.

Company	Underperform	Outperform
Centessa Pharmaceuticals	Outperform Votes 28 56.00%	Underperform Votes 22 44.00%
DICE Therapeutics	Outperform Votes 16 40.00%	Underperform Votes 24 60.00%

Do insiders & institutionals believe in CNTA or DICE?

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of DICE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk and volatility, CNTA or DICE?

Centessa Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, DICE Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Is CNTA or DICE more profitable?

DICE Therapeutics' return on equity of -22.01% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-63.08%	-42.97%
DICE Therapeutics	N/A	-22.01%	-20.79%

Does the media refer more to CNTA or DICE?

In the previous week, DICE Therapeutics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for DICE Therapeutics and 1 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 equaled DICE Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DICE Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate CNTA or DICE?

Centessa Pharmaceuticals currently has a consensus price target of $25.17, suggesting a potential upside of 55.93%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Centessa Pharmaceuticals is more favorable than DICE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
DICE Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has higher earnings and valuation, CNTA or DICE?

DICE Therapeutics has lower revenue, but higher earnings than Centessa Pharmaceuticals. DICE Therapeutics is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$6.85M	266.98	-$151.09M	-$1.56	-10.35
DICE Therapeutics	$1.13M	2,008.50	-$83.89M	-$2.34	-20.32

Summary

Centessa Pharmaceuticals beats DICE Therapeutics on 11 of the 16 factors compared between the two stocks.